| Name | Time | Description |
|---|---|---|
| Thursday, April 18, 2024 | ||
| Think Tank Session (by invitation only) | 2:00 PM - 5:00 PM | This invitation only sessions is moderated by Laurence Albiges and James Blackmur and is supported by Pfizer. Eisai has provided an unrestricted grant for this initiative and has had no influence on the content.
|
| Workshop: Cutting-Edge on Kidney: Advanced RCC Surgical Techniques & Team Dynamics for Young Urologists | 5:15 PM - 6:45 PM | Chair: Dr. Lars Lund
Program Highlights:
Pathway to Renal Surgery: This session will navigate through the career trajectory of a young urologist to becoming a renal surgeon. Gain insights into the necessary training, education, and hands-on experience required to excel in this specialty.
Surgical Techniques for Tumor Treatment: Delve into the complexities of various surgical approaches to kidney tumors. This session includes practical tips and tricks to tackle different tumor types, complemented by illustrative video clips to provide a visual learning experience.
Team Dynamics in Urology: Discuss the significance of collaboration and team synergy in surgical success. Discover the roles and responsibilities within a surgical team and how to effectively contribute to and lead a team in high-pressure environments.
Interactive Case Studies: This interactive session will focus on real-world cases, encouraging participants to engage, discuss, and learn from each other's experiences and perspectives. This workshop is an invaluable opportunity to learn from leading experts, refine your skills, and connect with peers in your field. Secure your spot today and take a significant step toward a successful career in renal surgery. |
| Pathway to Renal Surgery | 5:20 PM - 5:35 PM | Mie Thorlund, MD |
| Surgical Techniques for Tumor Treatment | 5:35 PM - 5:50 PM | Frode Nilssen, MD |
| Team Dynamics in Urology | 5:50 PM - 6:10 PM | Brad Leibovich, MD, Mayo Clinic and Christian Beisland, MD, PhD, University of Bergen |
| Interactive Case Studies | 6:10 PM - 6:45 PM | Panelists: Lars Lund, Mie Thorlund, Frode Nilssen, Brad Leibovich, Christian Beisland |
| Friday, April 19, 2024 | ||
| Session 1: Welcome & Indication for Surgery and Surgical Options | 8:30 AM - 9:30 AM | Chairs/Moderators: Lars Lund, MD, DMSci, Odense University Hospital and Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari |
| How to Manage Small Renal Masses | 8:38 AM - 8:48 AM | Enrique Trilla, MD, PhD, Vall d’Hebron Hospital Universitari |
| Debate: Management of Patients with Positive Partial Nephrectomy Margins | 8:48 AM - 9:03 AM | Axel Bex, MD, PhD, The Netherlands Cancer Institute and Arnaud Méjean, MD, PhD |
| Debate: Adjuvant Therapy for Some or All? | 9:03 AM - 9:18 AM | Thomas Powles, MD, MBBS, MRCP, Bart's Cancer Institute and Brian Rini, MD, Vanderbilt University Medical Center |
| Q & A | 9:18 AM - 9:28 AM | Chairs/Moderators: Lars Lund, MD, DMSci, Odense University Hospital and Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari |
| Session 2: Classifying RCC - A Panel Approach | 9:30 AM - 10:30 AM | Chairs/Moderators: Laurence Albiges, MD, PhD, Institut Gustave Roussy and Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla. IDIVAL |
| Surgical Approach | 9:35 AM - 9:45 AM | Bradley Leibovich, MD, PhD, Mayo Clinic |
| Molecular Approach | 9:45 AM - 9:55 AM | Samra Turajilic, MBBS, PhD, The Francis Crick Institute |
| Pathologist Approach | 9:55 AM - 10:05 AM | Ferran Algaba Arrea, MD, PhD, Universitat Autònoma de Barcelona |
| Oncologist Approach | 10:05 AM - 10:15 AM | Daniel Heng, MD, MPH, FRCPC, Tom Baker Cancer Centre |
| Q & A | 10:15 AM - 10:25 AM | Chairs/Moderators: Laurence Albiges, MD, PhD, Institut Gustave Roussy and Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla. IDIVAL |
| Break | 10:15 AM - 11:00 AM | |
| Session 3: Pieter de Mulder Award Winner & Lecture | 10:30 AM - 10:50 AM | Introduction: Lisa Pickering, MD, Royal Marsden NHS Foundation Trust Award Winner: Manuela Schmidinger, MD, Medical University of Vienna |
| Session 4: Nonclear Cell RCC | 11:00 AM - 12:00 PM | Chairs/Moderators: Michael Staehler, MD, PhD, University of Munich and Ulka Vaishampayan , MBBS, University of Michigan |
| Papillary RCC - Biology and Treatment | 11:04 AM - 11:14 AM | Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari |
| Chromophobe - Biology and Treatment | 11:14 AM - 11:24 AM | Martin Voss, MD, Memorial Sloan Kettering Cancer Center |
| Translocation RCC - Biology and Treatment | 11:24 AM - 11:34 AM | Daniel Heng, MD, MPH, FRCPC, Tom Baker Cancer Centre |
| FH Deficient Tumors RCC | 11:34 AM - 11:44 AM | Yüksel Ürün, MD, Ankara University School of Medicine |
| Q & A | 11:44 AM - 11:58 AM | Chairs/Moderators: Michael Staehler, MD, PhD, University of Munich and Ulka Vaishampayan, MBBS, University of Michigan |
| Session 5: Patient perspective | 12:00 PM - 12:15 PM | Presenter: Dawn Dyson Presentation Slides Presenter: Weronika Wrzesinski Presentation Slides |
| Session 6: Oral Abstracts | 12:15 PM - 1:15 PM | Chairs/Moderators: Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari and David McDermott, MD, Dana-Farber/ Harvard Center - Beth Israel Deaconess Medical Center |
| ORAL ABSTRACT: An Integrated Clinicopathological-Molecular Classifier Optimizes Risk Stratification of Localised Clear Cell Renal Cell Carcinoma (ccRCC) | 12:29 PM - 12:39 PM | Zayd Tippu |
| ORAL ABSTRACT: Exploring and identifying differences in characteristics and outcomes between patients receiving cabozantinib plus nivolumab (CaboNivo) and sunitinib in CheckMate 9ER (CM9ER): a latent class analysis | 12:39 PM - 12:49 PM | David Cella |
| ORAL ABSTRACT: Extended follow-up of KEYNOTE-B61: First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinoma (nccRCC) | 12:49 PM - 12:59 PM | Martin Voss, MD, Memorial Sloan Kettering Cancer Center |
| ORAL ABSTRACT: Efficacy by baseline characteristics in the phase 3 LITESPARK-005 study of belzutifan versus everolimus for previously treated advanced clear-cell renal-cell carcinoma (ccRCC) | 12:59 PM - 1:09 PM | Laurence Albiges, MD, PhD, Institut Gustave Roussy |
| Q & A | 1:09 PM - 1:15 PM | Chairs/Moderators: Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari and David McDermott, MD, Dana-Farber/ Harvard Center - Beth Israel Deaconess Medical Center |
| Posters & Lunch | 1:15 PM - 2:30 PM | |
| Non-CME Industry Symposium: New Treatment Options for locoregional RCC and advanced RCC post-IO and -TKI” – Presented by MSD | 1:25 PM - 2:25 PM | Speakers: Daniel Heng, Marc-Oliver Grimm, Cristina Suarez, Eric Jonasch |
| Session Intro & KCA Updates | 2:30 PM - 2:48 PM | Chairs/Moderators: Samra Turajlic, MBBS, PhD, The Francis Crick Institute and Lisa Pickering, MD, Royal Marsden NHS Foundation Trust Presenter: Salvo LaRosa PhD Kidney Cancer Association |
| Session 7: Debate: Systemic Therapy | 2:30 PM - 3:35 PM | Chairs/Moderators: Samra Turajlic, MBBS, PhD, The Francis Crick Institute and Lisa Pickering, MD, Royal Marsden NHS Foundation Trust |
| Debate: Combinations of Immune Checkpoint Inhibitors or IO TKI in Intermediate and Poor Risk Patients | 2:48 PM - 2:58 PM | Laurence Albiges MD, PhD, Institut Gustave Roussy and Manuela Schmidinger, MD, Medical University of Vienna |
| Debate: IO Containing Therapy vs TKI Monotherapy in Favorable Risk Patients | 2:58 PM - 3:08 PM | Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari and Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla. IDIVAL |
| Debate: What Should be the Comparator Arm for Future First-Line Trials? | 3:08 PM - 3:18 PM | Martin Voss, MD, Memorial Sloan Kettering Cancer Center and Bernard Escudier, MD, Institut Gustave Roussy |
| Panel Discussion | 3:18 PM - 3:33 PM | Chairs/Moderators: Samra Turajlic, MBBS, PhD, The Francis Crick Institute and Lisa Pickering, MD, Royal Marsden NHS Foundation Trust |
| Session 8: Management Approaches of Low Volume and Oligometastatic RCC | 3:35 PM - 4:30 PM | Chairs/Moderators: Manuela Schmidinger, MD, Medical University of Vienna and Lars Lund, MD, DMSci, Odense University Hospital |
| The Role of Radiation Therapy in Localized RCC Debate | 3:39 PM - 3:49 PM | Xavier Maldonado, MD, PhD, Vall d’Hebron Hospital Universitari |
| Radiation Therapy in Oliogometastic Disease | 3:49 PM - 3:59 PM | Raquibul Hannan, MD, PhD, UTSW |
| The Role of Nephrectomy in Metastatic RCC | 3:59 PM - 4:09 PM | Arnaud Méjean, MD, PhD, HEGP |
| Treatment of Residual RCC Following First-Line Systemic Therapy | 4:09 PM - 4:19 PM | Yüksel Ürün, MD, Ankara University School of Medicine |
| Q & A | 4:19 PM - 4:30 PM | Chairs/Moderators: Manuela Schmidinger, MD, Medical University of Vienna and Lars Lund, MD, DMSci, Odense University Hospital |
| Break--beverages available in the Auditorium Lobby | 4:30 PM - 4:40 PM | |
| Elevated soluble CD163 at baseline and increased PD1 expression on CD8pos T lymphocytes are associated with poor outcome in metastatic renal cell carcinoma. | 4:40 PM - 4:42 PM | Mie Wolff Kristensen |
| Session 9: Oral Poster ad Presentations | 4:40 PM - 4:51 PM | Chair: Lars Lund, MD, DMSci, Odense University Hospital |
| Multi-omics and spatial architecture of antigenic macrophage-CD8+ T cell crosstalk at the core of immune checkpoint blockade (ICB) response in advanced clear-cell renal cell carcinoma (aRCC) | 4:42 PM - 4:44 PM | Lisa Kinget |
| Patient-Derived Kidney Cancer Organoids to Predict Patient Therapeutic Responses | 4:44 PM - 4:46 PM | Isaac Toleman |
| Evaluation of bone response in metastatic renal cell carcinoma treated in 1st line with immunotherapy-based therapy | 4:46 PM - 4:48 PM | Fabien Moinard-Butot |
| Real-world characterization of patients treated with first-line checkpoint inhibitor-based combination therapy for advanced renal cell carcinoma: CARINA study post-hoc analysis | 4:48 PM - 4:50 PM | Paul Nathan, MD |
| Session 10: Women & Allies in RCC | 4:50 PM - 5:50 PM | Chair/Moderator: Ulka Vaishampayan, MBBS, University of Michigan Speaker Ann Francke, CEO of the Chartered Management Institute (CMI) in London and author of Create a Gender-Balanced Workplace, will lead a discussion on the importance of creating gender-inclusive workplaces, including common challenges when doing so and practical solutions to overcoming them. This session is open to both Women in RCC members and anyone who is an ally of this important KCA initiative. This event is sponsored by Exelixis and Bristol Myers Squibb. Eisai has provided an unrestricted grant for this initiative and has had no influence on the content. |
| Session Topic 1 - Determined by Chair | 4:56 PM - 5:06 PM | |
| Session Topic 2 - Determined by Chair | 5:06 PM - 5:16 PM | |
| Session Topic 3 - Determined by Chair | 5:16 PM - 5:26 PM | |
| Q & A | 5:26 PM - 5:50 PM | Chair/Moderator: Ulka Vaishampayan, MBBS, University of Michigan |
| Women and Allies in RCC Networking Reception | 5:30 PM - 6:00 PM | Continue the Conversation! Join Women in RCC session speaker Ann Francke, CEO of the Chartered Management Institute (CMI) in London and author of Create a Gender-Balanced Workplace, and other Women in RCC members for an informal networking session on Friday from 17:55-18:15. This networking is open to Women in RCC members and any woman who is an ally of this important KCA initiative, but registration is required. This event is sponsored by Exelixis and Bristol Myers Squibb. Eisai has provided an unrestricted grant for this initiative and has had no influence on the content.
|
| Evening Reception | 5:30 PM - 6:30 PM | |
| Poster Tour | 6:05 PM - 6:25 PM | Chairs: Annika Fendler, PhD, Charité - University Hospital Berlin and Michael Staehler, MD, PhD, University of Munich |
| Non-CME Industry Symposium: aRCC: Is your decision-making up-to-date? - Presented by Ipsen | 6:45 PM - 7:45 PM | Speakers: Prof. James Larkin (UK), Prof. Manuela Schmidinger (Austria), Prof. Laurence Albiges (France), Prof. Camillo Guglielmo Porta (Italy). Presented by Ipsen. |
| Dine & Connect | 8:00 PM - 10:30 PM | Who is invited: All attendees of the conference Restaurant Options: CAN LAURY L A T ABERNA DEL P UERTO PIERRE SITGES LA PIZZERIA DEL PORT |
| Saturday, April 20, 2024 | ||
| Young Investigators Breakfast | 8:30 AM - 9:30 AM | The Young Investigators Session is an opportunity for early-career healthcare providers to inquire about the different opportunities in the diverse fields of kidney cancer, such as academia, industry, private practice, and translational/basic research. As the leaders in these sectors, you will be asked to discuss your careers and answer questions from the audience. Moderator: Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari This event is sponsored by Pfizer. |
| Session 12: Welcome to Day 2 | 9:40 AM - 9:50 AM | Bradley Leibovich, MD, Mayo Clinic |
| Session 12: Molecular Mechanism of RCC | 9:50 AM - 10:50 AM | Chairs/Moderators: Annika Fendler, PhD, Charité - University Hospital Berlin and Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla. IDIVAL |
| Mouse Models of Kidney Cancer | 9:54 AM - 10:04 AM | James Brugarolas, MD, PhD, Harold C. Simmons Comprehensive Cancer Center - UT Southwestern |
| Genetic Tumor Evolution | 10:04 AM - 10:14 AM | Samra Turajlic, MBBS, PhD, The Francis Crick Institute |
| Computational Pathology to Enable Precision Medicine in ccRCC | 10:14 AM - 10:24 AM | Charlotte Spencer, MBBS, The Francis Crick Institute |
| Resistance to Immunotherapy | 10:24 AM - 10:34 AM | David Braun, MD, PhD, Yale School of Medicine |
| Translating Insights from the TME Into Novel Therapies for Kidney Cancer | 10:34 AM - 10:44 AM | David McDermott, MD, PhD, Dana-Farber/ Harvard Center - Beth Israel Deaconess Medical Center |
| Q & A | 10:44 AM - 10:50 AM | Chairs/Moderators: Annika Fendler, PhD, Charité - University Hospital Berlin and Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla. IDIVAL |
| Break | 10:50 AM - 11:00 AM | |
| Development of an EORTC Questionnaire for Quality of Life Assessment in Renal Cell Cancer Patients | 10:59 AM - 11:07 AM | Lisa Wintner, PhD, Tirol Kliniken |
| Session 14: Patient Advocacy - Implementation of Programs for Patients and Patient Organizations | 11:00 AM - 12:00 PM | Chairs/Moderators: Lars Lund, MD, DMSci Odense University Hospital and Dena Battle, KCCure |
| Unmet Need: Treating Bones Mets From Questions to Consensus | 11:02 AM - 11:10 AM | Berit Eberhard, Charité Comprehensive Cancer Center |
| How to Collect Data From Patient Experience | 11:10 AM - 11:18 AM | Juan Carlos Julian |
| Patient Perceptions and Engagement with Statistical Risk Models in RCC | 11:18 AM - 11:26 AM | Dena Battle, KCCure |
| Q & A | 11:26 AM - 12:00 PM | Chairs/Moderators: Lars Lund, MD, DMSci Odense University Hospital and Dena Battle, KCCure |
| Vogelzang Award | 12:00 PM - 12:20 PM | Introduction: Laurence Albiges, MD, PhD, Institut Gustave Roussy Award Recipient & Lecturer: Bernard Escudier, MD, Institut Gustave Roussy |
| Session 16: Novel Therapies/ Stem Cell/ Novel IO Approaches/ Static Session Beyond IO | 12:20 PM - 1:05 PM | Chairs/Moderators: Maxine Tran, MD, PhD, FRCS, MBBS, Royal Free Hospital, UCL Division of Surgery and Interventional Science and Guillermo De Velasco, MD, PhD, Lyx Institute of Urology |
| Beyond First-Line | 12:24 PM - 12:34 PM | Lisa Pickering, MD, Royal Marsden NHS Foundation Trust |
| Approvals Coming Soon | 12:34 PM - 12:44 PM | Eric Jonasch, MD, MD Anderson Cancer Center |
| Novel Approaches | 12:44 PM - 12:54 PM | Andrew Furness, MD, The Royal Marsden |
| Q & A | 12:54 PM - 1:05 PM | Chairs/Moderators: Maxine Tran, MD, PhD, FRCS, MBBS, Royal Free Hospital, UCL Division of Surgery and Interventional Science and Guillermo De Velasco, MD, PhD, Lyx Institute of Urology |
| Posters & Lunch | 1:05 PM - 2:20 PM | |
| Non-CME Industry Symposium: Answering the Unanswered – Presented by Eisai | 1:15 PM - 2:15 PM | Speakers: Prof. Thomas Powles, Prof. Laurence Albiges, Prof. Michael Staehler, Prof. Brian Rini This meeting is organized and sponsored by Eisai, Inc. |
| Session 17: Practice Changing Papers | 2:20 PM - 3:10 PM | Chairs/Moderators: Laurence Albiges, MD, PhD, Institut Gustave Roussy and Ulka Vaishampayan , MBBS, University of Michigan |
| Paper 1: KN564 | 2:23 PM - 2:29 PM | Panelist: Laura Bukavina, MD, MPH University Hospital |
| Discussant 1 | 2:29 PM - 2:35 PM | Panelist: Jean-Christophe Bernhard, MD, PhD, Université de Bordeaux |
| Paper 2: Contact 03 | 2:35 PM - 2:41 PM | Panelist: Kate Young, MBBS, MA, MD, (Res.), MRCP, Royal Marsden NHS Foundation Trust |
| Discussant 2 | 2:41 PM - 2:47 PM | Panelist: Viktor Grünwald MD, PhD, Universitätsklinikum Essen |
| Paper 3: Cosmic 313 | 2:47 PM - 2:53 PM | Panelist: Thomas Powles, MD, MBBS, MRC,P NHS Barts Health |
| Discussant 3 | 2:53 PM - 2:59 PM | Panelist: Sylvie Negrier, MD, PhD, UNICANCER |
| Panel Discussion and Q & A | 2:59 PM - 3:10 PM | Chairs/Moderators: Laurence Albiges, MD, PhD, Institut Gustave Roussy and Ulka Vaishampayan , MBBS, University of Michigan |
| The Christopher G. Wood Rising Star Award | 3:10 PM - 3:25 PM | Presented by: Bradley Leibovich, MD, Mayo Clinic Recipient: Rana R. McKay, MD, Associate Professor of Medicine and Urology at the University of California San Diego |
| Session 18: WoodFire | 3:25 PM - 4:05 PM | Chair/Moderator: Michael Staehler, MD, PhD, University of Munich Panelists: Axel Bex, MD, PhD, The Netherlands Cancer Institute Camillo Porta, MD, University of Bari 'A. Moro' Christian Beisland, MD, PhD, University of Bergen Sylvie Negrier, MD, PhD, UNICANCER Rana McKay, MD |
| Chairs Closing & Final Thoughts | 4:05 PM - 4:15 PM | Chairs/Moderators: Lars Lund, MD, DMSci, Odense University Hospital and Cristina Suárez Rodriguez, MD, PhD, Vall d’Hebron Hospital Universitari |